



From Jab to Lab: What Legislators Should Know



April 19, 2021

Winning the Fight Against COVID-19 – Where We Are Today

1

**Therapy Approved to
Treat COVID-19**

5

**Therapies Authorized
to Treat COVID-19**

3

**Vaccines Authorized
to Prevent COVID-19**

Developing Treatments and Vaccines to Fight COVID-19

There are **1794 clinical trials** under way across the globe for vaccinations and treatments.



Data as of 4/16/2021

Safety and Efficacy of Vaccines is a Priority for the Industry

Stringent regulatory standards
and requirements


Committed to FDA's
gold standard

Industry welcomed guidance

Monitoring continues

We are in a New Era of Medicine Where Breakthrough Science is Transforming Patient Care

53 New Medicines Were Approved by the FDA in 2020



Cancer Death Rate

Cancer death rate posts biggest one-year drop ever



Game Changer

Newly approved drug being called 'game changer' for people who suffer from hemophilia




Coronavirus Vaccine

Reasons for hope: the drugs, tests and tactics that may conquer coronavirus

Source: US FDA. Center for Drug Evaluation and Research (CDER) Advancing Health through Innovation. 2020 New Drug Approvals.
Note: Due to lack of data availability, novel approvals are not inclusive of medicines approved by the Center for Biologics Evaluation and Research (CBER) in 2020.

Many of America's Biopharmaceutical Companies Are Expanding Their Assistance Programs To Help More People




950+

public and private programs


The Medicine Assistance Tool (MAT) is a web platform designed to help patients, caregivers and health care providers learn more about some of the resources available to assist in affording their medicines.

www.MAT.org


Policies That Help *Patients Pay Less*



Share the savings



Make coupons count



Offer lower cost-sharing options



Cover medicines from day one




Hard-dollar cost sharing caps

Data Show Vaccine Confidence Along with Hesitancy

74%

“Yes” agree to take a COVID-19 vaccine or have already received at least one dose of a vaccine



Public Health Officials Have Offered Reassurance

“

I'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe and effective. We pledge to do our duty to the best of our ability, independently and without conflicts of interest, and we will be transparent about FDA decisions.

Dr. Peter Marks, FDA

“

“The speed was not at all at the sacrifice of safety. The speed was the reflection of extraordinary advances of vaccine platform technology – to be able to do things technically in months that some time ago may have taken several years...Speed means the science was extraordinary that got us here.”

Dr. Anthony Fauci, NSAID Director

Ensuring Diversity in Clinical Trials

- First Principles on Clinical Trial Diversity (released November 2020)

- **4 Primary Areas of Focus:**

- Educate the medical community and patients on the role of clinical trials
- Promote information about diversity and inclusion in clinical trial participation, build trust while acknowledging wrong doings
- Reduce barriers to clinical trial access (i.e. enrollment/ retention, trial design and eligibility criteria)
- Use data to enhance information on diverse populations beyond product approval

PHARMA STAT+

Pharma trade group issues guidelines for improving diversity of clinical trial participants

By NICHOLAS ST. FLEUR @SciFleur / NOVEMBER 17, 2020 Reprints

Stephen Ubl, PhRMA

Stephen Ubl, president and CEO of PhRMA, at the 2020 STAT Summit

STAT

The pharmaceutical industry's largest lobbying organization released guidelines on Tuesday to enhance racial and ethnic diversity among participants in clinical trials run by its member drug makers. The principles address a problem that has long hampered the development of new medicines and vaccines, including the studies of [potential Covid-19 shots](#).

Principles on Conduct of Clinical Trials
Communication of Clinical Trial Results



Clinical Trial Diversity

LEARN MORE

We're committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.